The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease

K. A. Polyzos; D. F. J. Ketelhuth

doi:10.5482/HAMO-14-10-0052

Hämostaseologie, Table of Contents

Hamostaseologie 2015; 35(02): 128-136
DOI: 10.5482/HAMO-14-10-0052

Review

Schattauer GmbH

The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease

An emerging fieldDie Rolle des Kynurenin-Pfades im Tryptophan-Stoffwechsel bei kardiovaskulären ErkrankungenEin neues Forschungsgebiet

K. A. Polyzos

¹Department of Medicine, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

,

D. F. J. Ketelhuth

¹Department of Medicine, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

› Author Affiliations

Abstract

Summary

Coronary heart disease and stroke, the deadliest forms of cardiovascular disease (CVD), are mainly caused by atherosclerosis, a chronic inflammatory disease of the artery wall driven by maladaptive immune responses in the vessel wall. Various risk factors for CVD influence this pathogenic process, including diabetes mellitus, hypertension, dyslipidaemia, and obesity. Indoleamine 2,3-dioxygenase (IDO), an enzyme catalyzing the rate-limiting step in the kynurenine pathway of tryptophan degradation, is strongly induced by inflammation in several tissues, including the artery wall. An increasing body of evidence indicates that IDO promotes immune tolerance, decreases inflammation, and functions as a homeostatic mechanism against excessive immune reactions.

This review provides an overview of the emerging field of the kynurenine pathway of tryptophan degradation in CVD, emphasizing the role of IDO-mediated tryptophan metabolism and its metabolites in the modulation of ‘classical’ cardiovascular risk factors, such as hypertension, obesity, lipid metabolism, diabetes mellitus, and in the development of atherosclerotic CVD.

Zusammenfassung

Ursache der koronaren Herzkrankheit und des Schlaganfalls, den tödlichsten Formen der Herz-Kreislauf-Krankheit (CVD), ist vor allem die Atherosklerose, eine chronisch-entzündliche Erkrankung der Arterienwand, die durch eine maladaptive Immunantwort in der Gefäßwand in Gang gehalten wird. Verschiedene Risikofaktoren für CVD beeinflussen diesen Krankheitsprozess, darunter Diabetes mellitus, Hypertonie, Dyslipidämie und Adipositas. Die Indolamin-2,3-Dioxygenase (IDO) ist ein Enzym, das als Katalysator für den umsatzlimitierenden Schritt im Kynurenin-Stoffwechselweg beim Abbau von Tryptophan dient und in verschiedenen Geweben, u. a. der Gefäßwand, infolge entzündlicher Vorgänge stark aktiviert wird. Es mehren sich die Belege dafür, dass IDO die Immuntoleranz fördert, Entzündungen reduziert und eine ausgleichende Funktion gegen überschießende Immunreaktionen hat.

In diesem Review geben wir einen Überblick über das neue Forschungsgebiet zum Kynurenin-Stoffwechselweg des Tryptophanabbaus bei CVD, mit Schwerpunkt auf der Rolle des IDO-vermittelten Stoffwechsels von Tryptophan und seiner Abbauprodukte bei der Modulation “klassischer” kardiovaskulärer Risikofaktoren wie Hypertonie, Adipositas, Lipidstoffwechsel oder Diabetes mellitus, und bei der Entwicklung einer atherosklerotischen CVD.

Keywords

Tryptophan - kynurenine - indoleamine - inflammation - cardiovascular - atherosclerosis - obesity - diabetes - lipids - cholesterol - hypertension - stroke

Schlüsselwörter

Tryptophan - Kynurenin - Indolamin - Entzündung - kardiovaskulär - Atherosklerose - Adipositas - Diabetes - Lipide - Cholesterin - Hyper tonie - Schlaganfall

Full Text

References

References
1 Mendis S, Puska P B N. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization; 2011
2 Heidenreich PA, Trogdon JG, Khavjou OA. et al. Forecasting the future of cardiovascular disease in the United States. Circulation 2011; 123: 933-944.
3 Ketelhuth DF, Gistera A, Johansson DK, Hansson GK. T cell-based therapies for atherosclerosis. Curr Pharm Des 2013; 19: 5850-5858.
4 Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis. Thromb Haemost 2011; 106: 779-786.
5 Hermansson A, Ketelhuth DF, Strodthoff D. et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081-1093.
6 Klingenberg R, Ketelhuth DF, Strodthoff D. et al. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(−)/(−) mice. Immunobiology 2012; 217: 540-547.
7 Lundberg AM, Ketelhuth DF, Johansson ME. et al. Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res 2013; 99: 364-373.
8 Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003; 170: 5809-5813.
9 Sakurai K, Zou JP, Tschetter JR. et al. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129: 186-196.
10 Szanto S, Koreny T, Mikecz K. et al. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther 2007; 09: R50.
11 Taher YA, Piavaux BJ, Gras R. et al. Indoleamine 2,3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J Allergy Clin Immunol 2008; 121: 983-991.
12 Gurtner GJ, Newberry RD, Schloemann SR. et al. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003; 125: 1762-1773.
13 Frostegard J, Ulfgren AK, Nyberg P. et al. Cytokine expression in advanced human atherosclerotic plaques. Atherosclerosis 1999; 145: 33-43.
14 Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells. Infect Immun 2002; 70: 3959-3961.
15 Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003; 81: 247-265.
16 Kotake Y, Masayama T. Über den Mechanismus der Kynureninbildung aus Tryptophan. Z Physiol Chem 1936; 243: 237-244.
17 Yamamoto S, Hayaishi O. Tryptophan pyrrolase of rabbit intestine. J Biol Chem 1967; 242: 5260-5266.
18 Werner-Felmayer G, Werner ER, Fuchs D. et al. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line upon cytokine treatment. Cancer Res 1990; 50: 2863-2867.
19 Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004; 04: 12-17.
20 Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981; 72: 411-412.
21 Nakagami Y, Saito H, Katsuki H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn J Pharmacol 1996; 71: 183-186.
22 Parsons CG, Danysz W, Quack G. et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor. J Pharmacol Exp Thera 1997; 283: 1264-1275.
23 Hilmas C, Pereira EF, Alkondon M. et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression. J Neurosci 2001; 21: 7463-7473.
24 Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010; 36: 211-218.
25 Erhardt S, Blennow K, Nordin C. et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-98.
26 Fukui S, Schwarcz R, Rapoport SI. et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991; 56: 2007-2017.
27 Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002; 01: 609-620.
28 Munn DH, Zhou M, Attwood JT. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
29 Munn DH, Shafizadeh E, Attwood JT. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372.
30 Lee GK, Park HJ, Macleod M. et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002; 107: 452-460.
31 Munn DH, Sharma MD, Baban B. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22: 633-642.
32 Uyttenhove C, Pilotte L, Theate I. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 09: 1269-1274.
33 Brandacher G, Perathoner A, Ladurner R. et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumorinfiltrating T cells. Clin Cancer Res 2006; 12: 1144-1151.
34 Munn DH, Sharma MD, Hou D. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-290.
35 Terness P, Bauer TM, Rose L. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells. J Exp Med 2002; 196: 447-457.
36 Fallarino F, Grohmann U, Vacca C. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 09: 1069-1077.
37 Iken K, Liu K, Liu H. et al. Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. Am J Respir Cell Mol Biol 2012; 47: 405-416.
38 Hiramatsu R, Hara T, Akimoto H. et al. Cinnabarinic acid generated from 3-hydroxyanthranilic acid strongly induces apoptosis in thymocytes through the generation of reactive oxygen species and the induction of caspase. J Cell Biochem 2008; 103: 42-53.
39 Lee SM, Lee YS, Choi JH. et al. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol Lett 2010; 132: 53-60.
40 Mezrich JD, Fechner JH, Zhang X. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-3198.
41 Pallotta MT, Orabona C, Volpi C. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12: 870-878.
42 Wang Y, Liu H, McKenzie G. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16: 279-285.
43 Changsirivathanathamrong D, Wang Y, Rajbhandari D. et al. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Crit Care Med 2011; 39: 2678-2683.
44 Khan IM, Stanislaus S, Zhang L. et al. Spinal nicotinic receptor activity in a genetic model of hypertension. Clin Exp Hypertens 2001; 23: 555-568.
45 Ito S, Komatsu K, Tsukamoto K, Sved AF. Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension 2000; 35: 413-417.
46 Kwok JB, Kapoor R, Gotoda T. et al. A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats. J Biol Chem 2002; 277: 35779-35782.
47 Kapoor V, Kapoor R, Chalmers J. Kynurenic acid, an endogenous glutamate antagonist, in SHR and WKY rats. Clin Exp Pharmacol Physiol 1994; 21: 891-896.
48 Mizutani K, Sugimoto K, Okuda T. et al. Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. Hypertens Res 2002; 25: 135-140.
49 Xu H, Barnes GT, Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
50 Niinisalo P, Raitala A, Pertovaara M. et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors. Scand J Clin Lab Invest 2008; 68: 767-770.
51 Pertovaara M, Raitala A, Juonala M. et al. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis. Clin Exp Immunol 2007; 148: 106-111.
52 Mangge H, Summers KL, Meinitzer A. et al. Obesity-related dysregulation of the tryptophan-kynurenine metabolism. Obesity 2014; 22: 195-201.
53 Wolowczuk I, Hennart B, Leloire A. et al. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women. Am J Physiol Regul Integr Comp Physiol 2012; 303: R135-R143.
54 Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate. Mol Psychiatry 2007; 12: 988-1000.
55 Nagano J, Shimizu M, Hara T. et al. Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PloS one 2013; 08: e73404.
56 Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012; 15: 635-645.
57 Zhang L, Ovchinnikova O, Jonsson A. et al. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J 2012; 33: 2025-2034.
58 Chang MY, Smith C, DuHadaway JB. et al. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther 2011; 12: 1050-1058.
59 Oxenkrug GF, Turski WA, Zgrajka W. et al. Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res Treat 2013; 2013: 149247.
60 Munipally PK, Agraharm SG, Valavala VK. et al. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 2011; 117: 254-258.
61 Hattori M, Kotake Y, Kotake Y. Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol Enzymol 1984; 06: 221-228.
62 Okamoto H. Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol Cell Biochem 1981; 37: 43-61.
63 Lam CK, Chari M, Su BB. et al. Activation of N-methyl-D-aspartate receptors in the dorsal vagal complex lowers glucose production. J Biol Chem 2010; 285: 21913-21921.
64 Kotake Y, Ueda T, Mori T. et al. Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid. Acta Vitaminol Enzymol 1975; 29: 236-239.
65 Oxenkrug G, Tucker KL, Requintina P, Summergrad P. Neopterin, a marker of interferon-gammainducible inflammation, correlates with pyridoxal-5’-phosphate, waist circumference, HDL-cholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen 2011; 03: 48-52.
66 Shen J, Lai CQ, Mattei J, Ordovas JM, Tucker KL. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions. Am J Clin Nutr 2010; 91: 337-342.
67 Oxenkrug G. Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 2013; 48: 294-301.
68 Fallarino F, Volpi C, Zelante T. et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 2009; 183: 6303-6312.
69 Okamoto H, Yamamoto H. DNA strand breaks and poly(ADP-ribose) synthetase activation in pancreatic islets--a new aspect to development of insulin-dependent diabetes and pancreatic B-cell tumors. Princess Takamatsu Symp 1983; 13: 297-308.
70 Alexander AM, Crawford M, Bertera S. et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51: 356-65.
71 Grohmann U, Orabona C, Fallarino F. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 03: 1097-1101.
72 Poormasjedi-Meibod MS, Jalili RB, Hosseini-Tabatabaei A. et al. Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses. PloS one 2013; 08: e71044.
73 Sarkar SA, Wong R, Hackl SI. et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes 2007; 56: 72-79.
74 Sulo G, Vollset SE, Nygard O. et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol 2013; 168: 1435-1440.
75 Pedersen ER, Midttun O, Ueland PM. et al. Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011; 31: 698-704.
76 Wirleitner B, Rudzite V, Neurauter G. et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33: 550-554.
77 Kato A, Suzuki Y, Suda T. et al. Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 2010; 14: 418-424.
78 Ray KK, Morrow DA, Sabatine MS. et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-3078.
79 Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204: 309-314.
80 Pawlak K, Kowalewska A, Mysliwiec M, Pawlak D. 3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 and macrophage inflammatory protein-1beta in patients with chronic kidney disease. Clin Biochem 2010; 43: 1101-1106.
81 Pawlak K, Mysliwiec M, Pawlak D. Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci 2010; 55: 196-203.
82 Pawlak K, Brzosko S, Mysliwiec M, Pawlak D. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009; 204: 561-566.
83 Niinisalo P, Oksala N, Levula M. et al. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques. Ann Med 2010; 42: 55-63.
84 Cuffy MC, Silverio AM, Qin L. et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007; 179: 5246-5254.
85 Nakajima K, Yamashita T, Kita T. et al. Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 1963-1972.
86 Daissormont IT, Christ A, Temmerman L. et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ Res 2011; 109: 1387-1395.
87 Christen S, Thomas SR, Garner B, Stocker R. Inhibition by interferon-gamma of human mononu-clear cell-mediated low density lipoprotein oxidation. J Clin Invest 1994; 93: 2149-2158.
88 Pae HO, Oh GS, Lee BS. et al. 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis 2006; 187: 274-284.
89 Brouns R, Verkerk R, Aerts T. et al. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem Res 2010; 35: 1315-1322.
90 Darlington LG, Mackay GM, Forrest CM. et al. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 2007; 26: 2211-2221.
91 Gold AB, Herrmann N, Swardfager W. et al. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 2011; 08: 17.
92 Jackman KA, Brait VH, Wang Y. et al. Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemiareperfusion in mice. Naunyn-Schmiedebergs Arch Pharmacol 2011; 383: 471-481.
93 Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000; 21: 149-154.
94 Stone TW. Kynurenic acid antagonists and kynurenine pathway inhibitors. Exp Opin Invest Drugs 2001; 10: 633-645.
95 Gellert L, Fuzik J, Goblos A. et al. Neuroprotection with a new kynurenic acid analog in the fourvessel occlusion model of ischemia. Eur J Pharmacol 2011; 667: 182-187.
96 Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab 1992; 12: 400-407.
97 Sas K, Robotka H, Rozsa E. et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 2008; 32: 302-308.
98 Gigler G, Szenasi G, Simo A. et al. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 2007; 564: 116-122.
99 Moroni F, Cozzi A, Peruginelli F. et al. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv Exp Med Biol 1999; 467: 199-206. E.
100 Gellert L, Knapp L, Nemeth K. et al. Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion. Neuroscience 2013; 247: 95-101.